Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Next Previous
Trial Profile

A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Acalabrutinib; Ibrutinib; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors TG Therapeutics Inc

Most Recent Events

  • 23 Jan 2023 Status changed from active, no longer recruiting to discontinued.
  • 19 Jul 2022 Results (n=28) assessing add on approach for patients treated with ibrutinib in the front-line or R/R settings with detectable MRD, published in the Clinical Cancer Research.
  • 27 Jan 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top